ANGLE is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L).
ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress.
The primary application is the capture of circulating tumour cells (CTCs) in patient blood for:
· Early detection of cancer;
· Personalised cancer treatment;
· Monitoring of cancer patients during treatment; and
· Post-treatment monitoring of cancer patients in remission.
Cadence Minerals (KDNC)
Cadence is dedicated to smart investments for a greener world. The planet needs rechargeable batteries on a global scale – upcoming supersized passenger vehicles, lorries and buses – require lithium and other technology minerals to power their cells. Cadence is helping find these minerals in new places and extracting them in new ways, which will meet the demand of this burgeoning market. With over £20 million vested in key assets globally, Cadence is helping us reach tomorrow, today.
First Sentinel is a consortium of companies focused on alternative investments, specializing in equity and debt deals with appealing IRRs, as well as traditional Corporate Finance and Legal Services.
This consortium enables us to support our clients end to end, whether it be the individual investor or corporate offering.
First Sentinel PLC (NEX: FSEN) is an alternative investment company that provides growth capital for public and private company investments. (NEX: FSEN).
Plutus PowerGen (PPG)
SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.
The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.
SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.